CAS NO: | 134523-03-8 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
1 g | 电议 |
5 g | 电议 |
生物活性 | Atorvastatin hemicalcium salt (CI-981) is an orally active3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin hemicalcium salt inhibits human SV-SMC proliferation and invasion withIC50s of 0.39 μM and 2.39 μM, respectively[1][2][3]. | ||||||||||||||||
体外研究 (In Vitro) | Atorvastatin treatment decreases apoptosis of myocardial cells by down-regulating GRP78, caspase-12 and CHOP expression in myocardial cells after myocardial infarction, and the endoplasmic reticulum (ER) stress is activated in response to heart failure and angiotensin II (Ang II) stimulation[4]. | ||||||||||||||||
体内研究 (In Vivo) | Atorvastatin (20-30 mg/kg; oral gavage; once a day; for 28 days; ApoE–/–mice) treatment significantly reduces endoplasmic reticulum (ER) stress signaling proteins, the number of apoptotic cells, and the activation of Caspase12 and Bax in the Ang II-induced ApoE-/- mice. Proinflammatory cytokines such as IL-6, IL-8, IL-1β are all remarkably inhibited after Atorvastatin treatment[5].
| ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 577.67 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C33H34Ca0.5FN2O5 | ||||||||||||||||
CAS 号 | 134523-03-8 | ||||||||||||||||
中文名称 | 阿托伐他汀钙 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) | ||||||||||||||||
溶解性数据 | In Vitro: DMSO : ≥ 50 mg/mL(86.55 mM) H2O :< 0.1 mg/mL(insoluble) *"≥" means soluble, but saturation unknown. 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|